Jpmorgan Chase & CO Sarepta Therapeutics, Inc. Transaction History

Jpmorgan Chase & CO

$1.23 Trillion
Q4 2024

A detailed history of Jpmorgan Chase & CO transactions in Sarepta Therapeutics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 2,020,604 shares of SRPT stock, worth $208 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

2,020,604

Previous 2,198,883 8.11%

Holding current value

$208 Million

Previous $275 Million 10.54%

% of portfolio

0.02%

Previous 0.02%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q4 2024 Feb 12, 2025	SELL	$104.54 - $137.94 $18.6 Million - $24.6 Million	-178,279 Reduced 8.11%	2,020,604 $246 Million
Q3 2024 Dec 26, 2024	BUY	$124.33 - $156.75 $44.2 Million - $55.7 Million	355,114 Added 19.26%	2,198,883 $275 Million
Q3 2024 Nov 08, 2024	BUY	$124.33 - $156.75 $44.2 Million - $55.7 Million	355,114 Added 19.26%	2,198,883 $275 Million
Q2 2024 Dec 26, 2024	SELL	$113.33 - $163.85 $40.2 Million - $58.2 Million	-355,114 Reduced 16.15%	1,843,769 $291 Million
Q2 2024 Aug 12, 2024	BUY	$113.33 - $163.85 $1.72 Million - $2.49 Million	15,167 Added 0.83%	1,843,769 $291 Million
Q1 2024 Dec 26, 2024	SELL	$93.7 - $141.53 $34.7 Million - $52.4 Million	-370,281 Reduced 16.84%	1,828,602 $237 Million
Q1 2024 May 10, 2024	BUY	$93.7 - $141.53 $49.3 Million - $74.5 Million	526,045 Added 40.39%	1,828,602 $237 Million
Q4 2023 Dec 26, 2024	SELL	$67.31 - $124.76 $60.3 Million - $112 Million	-896,326 Reduced 40.76%	1,302,557 $126 Million
Q4 2023 Feb 12, 2024	SELL	$67.31 - $124.76 $223 Million - $412 Million	-3,305,758 Reduced 71.73%	1,302,557 $126 Million
Q3 2023 Nov 14, 2023	BUY	$102.5 - $123.59 $20.9 Million - $25.2 Million	204,222 Added 4.64%	4,608,315 $559 Million
Q2 2023 Aug 11, 2023	BUY	$106.4 - $157.19 $74.6 Million - $110 Million	701,149 Added 18.93%	4,404,093 $504 Million
Q1 2023 May 18, 2023	BUY	$117.53 - $155.99 $5.76 Million - $7.65 Million	49,049 Added 1.34%	3,702,944 $510 Million
Q1 2023 May 11, 2023	BUY	$117.53 - $155.99 $283 Million - $376 Million	2,410,448 Added 193.85%	3,653,895 $504 Million
Q4 2022 Feb 13, 2023	BUY	$100.86 - $132.13 $52.7 Million - $69 Million	522,434 Added 72.46%	1,243,447 $161 Million
Q3 2022 Nov 14, 2022	SELL	$75.71 - $119.24 $22.9 Million - $36.1 Million	-302,735 Reduced 29.57%	721,013 $79.7 Million
Q2 2022 Aug 11, 2022	SELL	$62.69 - $88.44 $4.2 Million - $5.92 Million	-66,918 Reduced 6.14%	1,023,748 $76.7 Million
Q1 2022 May 11, 2022	BUY	$63.15 - $90.42 $2.66 Million - $3.8 Million	42,043 Added 4.01%	1,090,666 $85.2 Million
Q4 2021 Feb 10, 2022	SELL	$77.28 - $99.42 $35.9 Million - $46.2 Million	-464,780 Reduced 30.71%	1,048,623 $94.4 Million
Q3 2021 Nov 12, 2021	BUY	$65.97 - $92.48 $99.8 Million - $140 Million	1,513,403 New	1,513,403 $140 Million

Others Institutions Holding SRPT

# of Institutions

536

Shares Held

87.4M

Call Options Held

1.55M

Put Options Held

1.35M

View Full List

About Sarepta Therapeutics, Inc.

Ticker SRPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 87,567,904
Market Cap $9.02B
Description
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...

More about SRPT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account

Jpmorgan Chase & CO Sarepta Therapeutics, Inc. Transaction History